InsiderTrades.com logo
William H. Lewis net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

William Lewis Biography and Net Worth

CEO of Insmed
Will joined Insmed in 2012 as President and Chief Executive Officer and as a member of the board of directors. He became chair of the board of directors in November 2018. Will is the former Co-Founder, President, and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), and previously spent more than 10 years working in investment banking in the U.S. and Europe. He also previously worked for the U.S. government. Will holds a Bachelor of Arts degree cum laude from Oberlin College as well as a Master of Business Administration and a Juris Doctor with Honors from Case Western Reserve University. Will serves as the chair of the board of trustees of BioNJ, the life sciences association for New Jersey. Will is a member of the board of trustees of Case Western Reserve University as well as a member of the board of the Helix Acquisition Corp.

What is William H. Lewis' net worth?

The estimated net worth of William H. Lewis is at least $22.92 million as of March 17th, 2025. Mr. Lewis owns 334,186 shares of Insmed stock worth more than $22,915,134 as of April 14th. This net worth estimate does not reflect any other assets that Mr. Lewis may own. Learn More about William H. Lewis' net worth.

How old is William H. Lewis?

Mr. Lewis is currently 50 years old. There are 3 older executives and no younger executives at Insmed. Learn More on William H. Lewis' age.

How do I contact William H. Lewis?

The corporate mailing address for Mr. Lewis and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at investor.relations@insmed.com. Learn More on William H. Lewis' contact information.

Has William H. Lewis been buying or selling shares of Insmed?

William H. Lewis has not been actively trading shares of Insmed during the last quarter. Most recently, William Lewis sold 18,750 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $77.03, for a transaction totalling $1,444,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares of the company's stock, valued at $25,742,347.58. Learn More on William H. Lewis' trading history.

Who are Insmed's active insiders?

Insmed's insider roster includes Roger Adsett (COO), Sara Bonstein (CFO), David Brennan (Director), Martina Flammer (Insider), William Lewis (CEO), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.

Are insiders buying or selling shares of Insmed?

In the last year, insiders at the biopharmaceutical company sold shares 36 times. They sold a total of 944,431 shares worth more than $63,830,848.84. The most recent insider tranaction occured on March, 17th when CEO William Lewis sold 18,750 shares worth more than $1,444,312.50. Insiders at Insmed own 4.6% of the company. Learn More about insider trades at Insmed.

Information on this page was last updated on 3/17/2025.

William H. Lewis Insider Trading History at Insmed

William H. Lewis Buying and Selling Activity at Insmed

This chart shows William Lewis's buying and selling at Insmed by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Insmed Company Overview

Insmed logo
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
Read More

Today's Range

Now: $68.57
Low: $64.35
High: $68.63

50 Day Range

MA: $76.20
Low: $64.81
High: $83.83

2 Week Range

Now: $68.57
Low: $21.92
High: $84.91

Volume

1,823,424 shs

Average Volume

2,275,449 shs

Market Capitalization

$12.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07